Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

NovaBay Raises $6 Million from Hong Kong's OP Financial

publication date: Feb 12, 2018

NovaBay® Pharma, a Bay-area anti-microbial company, announced a new private placement of $6 million from OP Financial, a Hong Kong-listed investor. The transaction replaces one, announced two months ago, in which Ch-Gemstone Capital (Beijing) was supposed to invest $10.3 million in NovaBay stock. Plus, CG Capital planned to acquire $18 million in stock from public investors. The CG Capital investments were not approved by China regulators because of foreign investment worries. More details....

Stock Symbols: (NYSE American: NBY) (HK: 01140)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.